Relay Therapeutics, INC

Relay Therapeutics announced an amendment to its common stock sales agreement, increasing the at-the-market offering program to $462.98 million and reported its second quarter 2026 financial results, including a net loss of $83.7 million.

Relay Therapeutics stockholders approved an increase in authorized common stock from 300 million to 450 million shares at the 2026 Annual Meeting.

Relay Therapeutics has priced an underwritten public offering of common stock to raise approximately $296.8 million in net proceeds.

Relay Therapeutics announced initial Phase 2 ReInspire trial data for zovegalisib in vascular anomalies, showing a 60% volumetric response rate and strong patient-reported outcomes, with a favorable safety profile for chronic use.

Relay Therapeutics reported Q1 2026 financial results, highlighting progress in its zovegalisib program for breast cancer and vascular anomalies, and initiated a Phase 1/2 trial for RLY-8161.

Relay Therapeutics announced positive clinical data for its zovegalisib triplet combination, supporting advancement to Phase 3 development for frontline metastatic breast cancer.

Relay Therapeutics reported a reduced net loss in Q3 2025 and for the nine months ended September 30, 2025, driven by lower operating expenses and strategic portfolio adjustments, extending its cash runway into 2029.

Relay Therapeutics reported a reduced net loss in Q2 2025, driven by lower R&D and G&A expenses, and extended its cash runway into 2029, despite the termination of its Genentech collaboration.

Relay Therapeutics announces its Q1 2025 financial results, highlighting progress in clinical trials and strategic program prioritization.

Relay Therapeutics reports a net loss of $88.1 million for the third quarter of 2024, while also announcing a strategic shift in its pipeline and plans to seek a commercialization partner for one of its lead assets.

Relay Therapeutics reports a net loss of $92.2 million for the second quarter of 2024, while highlighting progress in clinical trials and discovery programs.

Relay Therapeutics reported a net loss of $81.4 million for the first quarter of 2024, with revenue driven by a milestone payment from the Genentech collaboration.

Relay Therapeutics' 2025 annual report highlights significant clinical progress for its lead candidate zovegalisib, including FDA Breakthrough Therapy designation, alongside strategic financial adjustments.

Relay Therapeutics' 10-K filing summarizes the company's financial results for 2024, highlights the clinical progress of RLY-2608, and outlines its strategy for pipeline expansion in precision oncology and genetic diseases.

Relay Therapeutics' 10-K filing details the company's capital structure, registration rights, anti-takeover provisions, and other corporate governance matters.

Sanjiv Patel, President and CEO and a Director of Relay Therapeutics, Inc., sold 48,199 shares of common stock on August 17, 2026 for $20.33 per share.

Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics, Inc., sold 17,717 shares of common stock on August 14, 2026 for $19.74 per share.

Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics, Inc., sold 1,459 shares of common stock on July 28, 2026 for $18.61 per share.

Peter Rahmer, See remarks of Relay Therapeutics, Inc., sold 748 shares of common stock on July 28, 2026 for $18.61 per share.

Donald A Bergstrom, President, R&D of Relay Therapeutics, Inc., sold 2,237 shares of common stock on July 28, 2026 for $18.61 per share.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, Inc., reported the sale of 8,660 shares of common stock for $18.71 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Relay Therapeutics announces its annual stockholders meeting to be held on June 6, 2025, covering director elections, executive compensation, and auditor ratification.

Relay Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 6, 2025, to elect directors, vote on executive compensation, and ratify the appointment of its independent accounting firm.

Relay Therapeutics will hold its annual stockholders meeting on June 3, 2024, to elect directors, vote on executive compensation, and ratify the appointment of Ernst & Young LLP as the company's auditor.

Relay Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 3, 2024, to elect directors, vote on executive compensation, and ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 10.0% of Relay Therapeutics Inc.'s common stock as of July 31, 2026.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 9.4% of Relay Therapeutics' common stock as of June 30, 2026.

Point72 Asset Management and Steven A. Cohen have reported a 0% beneficial ownership stake in Relay Therapeutics, Inc.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has reported beneficial ownership of 438,471 shares, representing 9.99% of Kiora Pharmaceuticals, Inc.'s common stock, following a private placement.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Relay Therapeutics Inc. following an internal realignment.

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a 5.3% beneficial ownership stake in Relay Therapeutics, Inc.